Nabumetone, in contrast to etodolac, lacks gastrointestinal irritancy in the rat: Assessment by the inflammatory marker, haptoglobin, and blood loss Authors
Received: 26 January 1995 Accepted: 25 April 1995 DOI:
Cite this article as: Melarange, R., Gentry, C., Blower, P.R. et al. Inflammopharmacology (1995) 3: 259. doi:10.1007/BF02659123 Abstract
The aim of the present study was to compare the effects of the non-acidic anti-inflammatory drug, nabumetone, with those of etodolac on gastrointestinal mucosal integrity and blood loss in the rat. Gastrointestinal damage was absent in nabumetone-treated animals even at a high anti-inflammatory dose (79 mg/kg). Plasma haptoglobin, a marker of mucosal integrity, and caecal haemoglobin, a measure of blood loss, were also unchanged compared with controls. In contrast, etodolac induced both gastric (ED
50 30 mg/kg) and ileal (ED 50 4.5 mg/kg) ulceration in a dose-related manner. Accompany-ing these changes were increases in haptoglobin concentration and blood loss. It is suggested that nabumetone’s lack of gastrointestinal irritancy may relate, in part, to its non-acidic nature and to its active metabolite’s (6MNA) differential effects on prostanoid production and lack of enterohepatic circulation. Keywords NSAIDs GI ulceration Plasma haptoglobin Blood loss References
Roth SH, Bennett, RE. Nonsteroidal anti-inflammatory drug gastropathy. Arch Intern Med. 1987;147:2039–100.
Armstrong CP, Blower AL. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 1987;28:527–32.
Aabakken L, Osnes M. Non-steroidal anti-inflammatory drug-induced disease in the distal ileum and large bowel. Scand J Gastroenterol. 1989;24(Suppl.163):48–55.
Grebb WH, Von Schrader HW, Cerlek S et al. Endoscopic studies of nabumetone in patients with rheumatoid arthritis. Am J Med. 1987;83(Supp..4B):19–24.
Lussier A, Davis A, Lussier Y et al. Comparative gastrointestinal blood loss associated with placebo, aspirin and nabumetone as assessed by radiochromium. J Clin Pharmacol. 1989;29:225–9.
Lemmel EM, Stroehmann I. Experience with nabumetone in the treatment of rheumatic conditions - results of an application study in 18,047 patients. Fortschr Med. 1988;106:63–8.
Fleischmann RM. Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis. J Rheumatol. 199219(Suppl.36):32–40.
Roth SH. Upper gastrointestinal safety with nabumetone. J Rheumatol. 199219(Suppl.36):74–9.
Melarange R, Rashbrook LC. Comparison of the effects of nabumetone with indomethacin on rat gastric mucosal 6-keto-PGF1α production and on bile salt-induced changes in gastric mucosal function. J Pharm Pharmacol. 1987;39:717–20.
Dandona P, Jeremy JY. Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution? Drugs. 1990;40(Suppl.5):16–24.
Melarange R, Blower PR, Gentry C et al. Nabumetone, an effective anti-inflammatory agent, lacks the gastric irritancy potential of piroxicam or ibuprofen. Br J Pharmacol. 1990;99:172P.
Melarange R, Gentry C, O’Connell C et al. The anti-inflammatory drug nabumetone lacks the gastrointestinal damaging potential of loxoprofen or naproxen. Jap J Inflam. 1991;11:607–14.
Melarange R, Gentry C, O’Connell C et al. Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Comparative studies with indomethacin. Dig Dis Sci. 1992;37:1847–52.
Robert A. Cytoprotection by prostaglandins. Gastroenterology. 1979;77:761–7.
Lee D, Dvornik D. Etodolac: effect on prostaglandin concentrations in the gastric mucosa of rats. Life Sci. 1985;36:1157–62.
Lee DKH, Chau TT, Weichmann BM et al. Temporal relationships of the anti-inflammatory effect of etodolac in the adjuvant arthritic rat. Proc Soc Exp Biol Med. 1988;187:273–7.
Dvornik D, Lee DKH. Theoretical mechanism for the gastrointestinal safety of etodolac: Selective sparing of cytoprotective prostaglandins. Clin Rheumatol. 1989;8:16–24.
Clarke BS. A method for occult blood in faeces using non-carcinogenic reagents. Med Lab Tech. 1971;28:187–90.
Martel RR, Klicius J. Comparison in rats of the anti-inflammatory and gastric irritant effects of etodolac with several clinically effective anti-inflammatory drugs. Agents Actions. 1982;12:295–7.
Kent TH, Cardelli RM, Stamler FW. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol. 1969;54:237–49.
Satoh H, Inada I, Hirata T et al. Indomethacin produces gastric antral ulcers in the refed rat. Gastroenterology. 1981;81:719–25.
Bonney RJ, Glinka S, Hopple S et al. Assessment of gastric bleeding in rats: effects of cyclooxygenase inhibitors and 16,16-dimethyl prostaglandin E
on gastric bleeding. Agents Actions. 1987;21:310–13.
Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature (London) New Biol. 1971;231:235–7.
Nadell J, Bruno J, Varady J et al. Effect of naproxen and of aspirin on bleeding time and platelet aggregation. J Clin Pharmacol. 1974;14:176–82.
Patrono C, Ciabattoni G, Pugliese F et al. Inhibition of platelet cyclooxygenase by aspirin-like drugs: methods for
in vitro and ex vivo assessment. In: Brune K, Baggliolini M, eds. Arachidonic Acid Metabolism in Inflammation and Thrombosis. Agents Actions Suppl. Basel: Birkhauser; 1979;4:138–44.
Billingham MEJ, Tucker MJ. Correlation between the rise in acute phase proteins and histological evidence of ulceration in the rat following indomethacin treatment. Br J Pharmacol. 1979;67:450P.
Melarange R, Gentry C, Durie M et al. Gastrointestinal irritancy, antiinflammatory activity, and prostaglandin inhibition in the rat Differentiation of effects between nabumetone and etodolac. Dig Dis Sci. 1994;39:601–8.
Amos RS, Crockson RA, Crockson AP et al. Rheumatoid arthritis: C-reactive protein and erythrocyte sedimentation rate during initial treatment. Br Med J. 1978;1:1396.
Thoen J, Helgetveit K, Forre O et al. Effects of piroxicam and D-penicillamine on T lymphocyte subpopulations, natural killer cells and rheumatoid factor population in rheumatoid arthritis. Scand J Rheumatol. 1988;17:91–102.
Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993;268:6610–4.
Laneuville O, Breuer DK, DeWitt DL et al. Differential inhibition of human prostaglandin endoper- oxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 1994;271:927–34.
Patrignani P, Panara MR, Greco A et al. Biochemical and pharmacological characterisation of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271:1705–12.
Duggan DE, Hooke KF, Noll RM et al. Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem Pharmacol. 1975;25:1749–54.
Whittle BJR. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology. 1981;80:94–8.
Allison MC, Howatson AG, Torrance CJ et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med. 1992;327:749–54.
Morris AJ, Madhok R, Sturrock RD et al. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. Lancet. 1991;337:520.
Cayen MN, Kraml M, Ferdinandi ES et al. The metabolic disposition of etodolac in rats, dogs and man. Drug Metab Rev. 1981;12:339–62.
Brune K, Nurnberg B, Szelenyi I et al. The enterohepatic circulation of some anti-inflammatory drugs may cause intestinal ulcerations. In: Rainsford KD, Velo GP, eds. Side Effects of Anti-Inflammatory Drugs, Vol.3 (Part 2). Lancaster: MTP Press; 1985:29–40
Brett MA, Grebb WH, Kurth HJ et al. Absence of enterohepatic circulation of the active metabolite of nabumetone. Forsch Med. 1988;106:736–7.
Bjarnason I. Non-steroidal anti-inflammatory drug-induced enteropathy. In: Peters TJ, ed. The Cell Biology of Inflammation in the Gastrointestinal Tract. Hull: Corner & Co; 1990:345–60.
Bjarnason I, Fehilly B, Smethurst P et al. Importance of local
systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut. 1991;32:275–7.
Melarange R, Moore G, Blower PR et al. A comparison of indomethacin with ibuprofen on gastrointestinal mucosal integrity in conventional and germ-free rats. Aliment Pharmacol Ther. 1992;6:67–77.
PubMed CrossRef Copyright information
© Kluwer Academic Publishers 1995